Colfax, Inc - parent of DJO - is making moves ...
Post# of 7795
In my last post, I posited that the recent silence might have something to do w/ RecoveryRx and getting it included in insurance registries; CMS, VA, DOD, private insurance programs. Only an NDA could completely shut down communication like it has done. What is behind the NDA curtain is anybody's guess. I offer my interpretations for informational purposes only. I'm guessing like everyone else.
The key ingredient in getting our OEM partners was getting the FDAs full body musculo-skeletal clearance. I think the next step could very well be dependent upon us getting on these insurance registries. In much the same way the FDA clearance made us so attractive for OEM partnerships, our getting listed on insurance formularies will attract potential buyers (if not already) in that the buyer would not have to go thru the hassle of that laborious process.
Getting on these formularies is the final step in my estimation. After that it's all about execution of the business plan. The sales are already growing. We have a string of distribution deals on every continent and in every major market in the world. Check out the info below. DJO will become the "Orthopedic Device Giant". Every surgical procedure involves some level of pain and/or discomfort. Using PEMF for pain management and enhanced recovery could fit in nicely for this new med tech company.
https://www.massdevice.com/colfax-split-to-cr...ice-giant/ 05 Mar '21
19 Jan '21 - https://www.djoglobal.com/trilliantsurgical
26 Apr '21 - Colfax Announces DJO Acquires MedShape, Inc.
11 Dec '20 - Colfax Subsidiary DJO Acquires LiteCure Laser Therapy
13 Nov '20 - Colfax Arm DJO Acquires Stryker's Extremity Products
https://www.colfaxcorp.com/news-events/
a) Public Offering of 14,000,000 Shares of Common Stock
b) Separate Into Two Independent Public Companies
Medical Technology Company
The MedTech company is a leading, specialty medical technology growth company. It has top-tier positions in attractive orthopedic segments across the continuum of care, including surgical implants as well as injury prevention and recovery devices, with clear paths to further accelerate growth. The company recently completed several strategic bolt-on acquisitions, strengthening and expanding its position in attractive market segments including extremities reconstruction and therapeutic laser technology for recovery. The company will be comprised of Colfax’s current Medical Technology operating segment, which is expected to generate revenue of approximately $1.4 billion in 2021.
The separation is expected to enable MedTechCo to continue to expand its share in high-growth, high-margin served and adjacent markets through strategic M&A and R&D investments. This will position the company with significant opportunities to deliver above-market growth, margin improvement and increased cash flow. Capital deployment is expected to be focused on supporting the company’s strategic growth program.
later - WBeacham